aTyr Pharma, Inc. Q4 FY2022 earnings call

• aTyr is developing efzofitimod for inflammation and fibrosis, with Phase 3 study in pulmonary sarcoidosis (EFZO-FIT) enrolling, and expanding to Phase 2 study in SSc-ILD with FDA clearance. - Leveraging tRNA synthetase biology platform and collaboration with Dualsystems Biotech for discovery. - Financials: 2022 R&D $42.8M, G&A $14M; cash runway extends to 2026. - Plan to release quarterly results by press release only, focusing on transparency via press releases, presentations, etc.

No detailed product segment financial performance with absolute terms and revenue contribution % provided. Overall, research and development expenses for 2022 were $42.8 million, including clinical development, manufacturing, and R&D costs for efzofitimod and other programs. General and administrative expenses were $14 million. Cash position at year-end 2022 was $69.3 million, with subsequent $10 million milestone and $52 million from public offering.

• Cash runway is expected to fund through readout of efzofitimod clinical trials into 2026. - Intends to focus on executing 2 clinical trials and generating discovery targets. - Expect data from ATS conference on efzofitimod's mechanism of action. - EFZO-FIT trial readout expected in Q1 2025, SSc-ILD Phase 2 trial data expected in 2024.

Forward-looking statements involve risks and uncertainties as per Private Securities Litigation Reform Act, with actual results possibly differing from forward-looking statements. Risks detailed in SEC filings, including those in annual report, quarterly reports, etc.

Q: Could you provide more on the SSc-ILD trial and dosing in EFZO-FIT?

A: SSc-ILD was considered earlier, with preclinical data supporting efzofitimod; trial is 28-week, 25 patients, focusing on U.S. dosing is fixed (270 and 450 mg) to gain commercial knowledge.

Q: Plans for SSc-ILD trial initiation outside U.S. and Japan enrollment?

A: Current plan is to focus on U.S. leveraging existing sites; Japan enrollment trajectory is good, expecting ~10% of patients from Japan.

Q: Rationale for 12-week endpoint in SSc-ILD trial and positioning of efzofitimod?

A: 12-week endpoint to look at skin readouts early; efzofitimod could be add-on first-line therapy for SSc-ILD, working with or without mycophenolate.